A Multiattribute-utility-function Approach to Weighing the Risks and Benefits of Pharmaceutical Agents

Eriksen, Stuart P.; Keller, L. Robin

doi:10.1177/0272989x9301300205

Cited by 24 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to application of MAU analysis in product development decisions that pharmaceutical companies make, even formulary committees have utilized such MAU decision analytics after product is marketed, to compare medication alternatives when numerous variables need to be considered in the decision-making process (23). MAU analysis has also been shown to have value when evaluating a NME for advancing through preclinical stages through early clinical development when decisions are based on a combined analysis of the available preclinical and early clinical data (24).…”

Section: Multi-attribute Utility Analysismentioning

confidence: 99%

The Use of Clinical Utility Assessments in Early Clinical Development

Khan

Perlstein

Krishna

2009

AAPS J

View full text Add to dashboard Cite

Abstract. A quickly realizable benefit of model-based drug development is in reducing uncertainty in risk/benefit, comprising individually of safety and effectiveness, two key attributes of a product evaluated for regulatory approval, marketing, and use. In this review, we investigate gaps and opportunities in using fundamental decision analytic principles in drug development and present a quantitative clinical pharmacology framework for the application of such aids for early clinical development decision making. We anticipate that implementation of such emerging tools will enable sufficient scientific understanding of the two attributes to facilitate the early termination of compounds with less than desirable risk/benefit profiles and continuance of compounds with acceptable risk/benefit profiles.

show abstract

Section: Multi-attribute Utility Analysismentioning

confidence: 99%

The Use of Clinical Utility Assessments in Early Clinical Development

Khan

Perlstein

Krishna

2009

AAPS J

View full text Add to dashboard Cite

show abstract

“…Such decisions under risk can be extended to have multiple objectives rather than just a single objective (which is usually to maximize a monetary measure). For examples of multiobjective utility models for medical decisions, see Simon [25] and Eriksen and Keller [8].…”

Section: Tutorials In Operations Research C 2009 Informsmentioning

confidence: 99%

“…Once we have the objectives listed, if we are using an additive preference model, 8 we can represent those preferences using "swing weights." We assign to each lowest level objective in the hierarchical tree a weight that indicates how much importance is being placed on it.…”

Section: Put Weights On Objectives For An Additive Multiple-objectivementioning

confidence: 99%

Multiple-Objective Decision Analysis Involving Multiple Stakeholders

Keller¹,

Merage²,

Simon³

et al. 2009

Decision Technologies and Applications

Self Cite

View full text Add to dashboard Cite

Many operations researchers know about the use of decision analysis to help decide among alternative investments (such as pharmacological research and development investments) using decision trees with chance nodes to compute expected monetary value or return on investment of different alternatives. Such an analysis often aims to maximize a single evaluation measure for a single decision maker. We demonstrate less widely known decision analysis techniques using spreadsheet models that will help analysts understand and model the multiple objective perspectives of the stakeholders to a decision. Using this approach can aid in identifying mutually agreeable alternative actions, designing new and better alternatives, and foreseeing opposition to decisions. It can also help analysts understand the evolution of past decisions from multiple perspectives.In some cases, one objectives hierarchy can be suitable for a set of stakeholders, and differences in opinions across stakeholders can be characterized by differences in weights on the multiple objectives. Examples include the analysis for the merger of the Operations Research Society of America and The Institute of Management Sciences to become INFORMS, Arizona water resources planning, and planning for protection against radioactive iodine releases in nuclear incidents. In other cases, an objectives hierarchy will be constructed for each stakeholder because their objectives are so different that construction of separate hierarchies better represents their divergent perspectives. Examples include a tuna fish supplier source selection decision (from the perspectives of StarKist, environmentalists, and the San Diego tuna fishing fleet), the potential siting of a new Home Depot in San Juan Capistrano (from the perspectives of Home Depot, the city, residents, and competing or complementary small businesses), and a prostate cancer treatment decision (from the perspectives of former Intel CEO Andy Grove, his family, his company, and his doctors).

show abstract

“…public-sector and business settings; however, their use in selecting drug products appears to be relatively limited, although a number of reports have appeared in the literature over the past decade or so [13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project

Dodick

Lipton²,

Ferrari³

et al. 2004

Current Science Inc

View full text Add to dashboard Cite

Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.

show abstract

A Multiattribute-utility-function Approach to Weighing the Risks and Benefits of Pharmaceutical Agents

Cited by 24 publications

References 10 publications

The Use of Clinical Utility Assessments in Early Clinical Development

The Use of Clinical Utility Assessments in Early Clinical Development

Multiple-Objective Decision Analysis Involving Multiple Stakeholders

Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project

Contact Info

Product

Resources

About